General Hospital Of Thessaloniki O Agios Dimitrios
- Address
- Elenis Zografou 2, 546 34 Thessaloniki, Greece
General Hospital Of Thessaloniki O Agios Dimitrios - Sepsis Research Center
General Hospital Of Thessaloniki O Agios Dimitrios is actively engaged in cutting-edge clinical research focused on critical care medicine and advanced sepsis management. The center is contributing to groundbreaking international collaborative studies that aim to transform the treatment paradigm for life-threatening infections through precision medicine approaches.
- Interferon-gamma driven sepsis endotype identification and treatment
- Novel immunomodulatory therapies for critical care patients
- Biomarker-guided precision medicine in sepsis management
The hospital is participating in the EMBRACE trial, a pivotal study investigating emapalumab, a monoclonal antibody targeting interferon-gamma activity, for patients with IFNγ-Drive Sepsis (IDS). This innovative research addresses a critical unmet need in sepsis care, as the IDS endotype affects nearly 20% of sepsis patients and carries a 28-day mortality rate of 40-43%. By focusing on endotype-specific treatment strategies, the center contributes to advancing personalized approaches in critical care medicine and improving outcomes for patients with this high-risk sepsis phenotype.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 173 other sites in Greece
Therapeutic Area Benchmark — Greece
Select a therapeutic area to compare against other sites in Greece.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Greece
Market Share
Country: Greece
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in General Hospital Of Thessaloniki O Agios Dimitrios
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Emapalumab in Patients with Interferon-Gamma Driven Sepsis: A Randomized, Placebo-Controlled Trial | Elliniko Institouto Meletis Tis Sipsis | Phase II | Not Recruiting | Mar 2025 | Mar 2026 |
IMP list
lock Showing 1 of 2 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Emapalumab | 1 | Unknown | 2025-03-12 | 2025-03-12 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.